AzTrials
AzTrials

Transgender PersonsTRANSPOSENCT06854965

Cohort Study on Factors Associated with the Evolution of Quality of Life Among Transgender Individuals in the French Population

An observational study of Transgender Persons, run by CNGE Conseil at 1 site in France.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This research focuses on identifying medical, social, and healthcare journey determinants associated with the evolution of quality of life in the transgender population at 12 months. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Transgender Persons
How many people
1,500 participants
Where
1 siteFrance
Study dates
28 Feb 2025to 28 Feb 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Transgender Individuals

Who may be able to join

  • Person identifying themselves as trans
  • Person of legal age (≥ 18 years)
  • Person living in France
  • Person who has not expressed any opposition after receiving full information about the protocol
  • Person who understands and speaks French, or who is an allophone speaking English, Spanish or Portuguese

Who cannot join

  • People who do not understand or speak French, English, Spanish or Portuguese.
  • Person under guardianship or curatorship, under legal protection or under safeguard of justice
  • Anyone who has expressed their opposition after receiving full information about the protocol.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

El Mountacer Billah EL ABBASSI, Ph.D contact

+33 (0)763054551

e.elabbassi@cnge.fr

France1 site
  • CNGE Conseil

    Paris, 75011

    El Mountacer Billah EL ABBASSI, Ph.D, +33 (0)763054551, e.elabbassi@cnge.fr

Other trials in France

About this study

This research focuses on identifying medical, social, and healthcare journey determinants associated with the evolution of quality of life in the transgender population at 12 months. To address the research question, it is planned to include 1,500 transgender individuals, among those attending healthcare professionals or associations in the French territory who have agreed to take on the role of investigators (professionals in healthcare or designated individuals within an association).

Read the detailed description

Information Note:

  1. What is the purpose of this research? This research focuses on identifying medical, social, and healthcare journey determinants associated with the evolution of quality of life in the transgender population at 12 months. To address the research question, it is planned to include 1,500 transgender individuals, among those attending healthcare professionals or associations in the French territory who have agreed to take on the role of investigators (professionals in healthcare or designated individuals within an association).
  2. What does the research involve? In the proposed research, the investigators will assess quality of life through a standardized questionnaire. The investigators will analyse this quality of life in relation to various collected data concerning participants social context, medical data, mental health, transition journey, isolation and violence, as well as participants use of psychoactive substances. In the framework of this research, an initial questionnaire will be administered at time T0, during participants appointment (either via video call or in person) with a health mediator. A second questionnaire will be administered 6 months later during a second appointment (via video call or in person) with a health mediator. Finally, a third and final questionnaire will be administered 12 months after T0 during a final appointment (via video call or in person) with a health mediator. The aim of these various questionnaires is to assess the evolution of quality of life over a period of 12 months. Each questionnaire will take a maximum of 40 minutes to complete.
  3. What is the research timeline? The expected duration of the research is 2 years, and the participation will be for 12 months. If person agree to participate in this research, the course of the research will be as follows: A health mediator will schedule a video (or if impossible, in-person) interview with participant. Health mediators are professionals whose role is dedicated to reducing social health inequalities. They create interfaces between various stakeholders in the healthcare system and individuals facing challenges in their healthcare and prevention journeys due to various vulnerabilities. The goal is to assist these individuals in engaging with and successfully navigating these pathways, while considering their living environment. The first questionnaire will then be completed: some sections will be filled out by participants, while other questions will be asked directly by the health mediator. The health mediator will contact participants subsequently to arrange the 6-month and 12-month interviews, which will proceed in the same manner. The maximum time between the presentation of the information note and the contact by the health mediator is 1 month.
  4. What are the benefits of participation? By participating in this research, participants will contribute to a better understanding of the factors associated with the evolution of quality of life in transgender individuals. Moreover, participation in the 3 questionnaires (0, 6 months, 12 months) will entitle participant to receive a gift card worth €20 as a token of appreciation for participation. If there is a need to travel to complete the questionnaires in person, the travel expenses will be covered by the sponsor.
  5. How will the collected data be processed for the research? As part of the research in which participants are invited to participate, processing of personal data will be carried out by CNGE Conseil, the research sponsor and data controller, to analyse the results.

This processing is necessary for conducting the research which serves the public interest mission entrusted to CNGE Conseil.

For this purpose, participants medical data and data regarding participants lifestyle habits, as well as ethnic origins or data relating to sexual life, will be transmitted to the Sponsor or to individuals or companies acting on its behalf, in France. This data will be identified by a participants data may be used for subsequent research or additional analyses related to this research in collaboration with private or public partners, in France or abroad, under conditions ensuring their confidentiality and the same level of protection as European legislation. Participants may oppose at any time to the subsequent use of participants data by contacting the qualified person who proposed participation in this research project. Participants data will be retained only for the period strictly necessary and proportionate to the purpose of the research. They will be kept in the information systems of the data controller for up to two years after the last publication of the research results.

Participants data will then be archived in accordance with applicable regulations (article R1123-63 of the French Public Health Code). The archiving of research documents will be for a minimum of 15 years.

Keywords
Transgender, Quality of Life (QoL)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in quality of life (WHOQOL-BREF) between 0 and 12 months.

    Differences in the WHOQOL-BREF between 0 and 12 months. The WHOQOL-BREF (World Health Organization Quality Of Life tool) consists of four dimensions: physical health, psychological health, social relationships and environment, with scores ranging from 0 to 100. A higher score denotes a higher quality of life.

    Measured: From enrollment to the last questionnaire at 12 months

Secondary outcomes (12)
  1. Quality of life (WHOQOL-BREF) at baseline and 6 months

    WHOQOL-BREF at baseline and 6 months. The WHOQOL-BREF (World Health Organization Quality Of Life tool) consists of four dimensions: physical health, psychological health, social relationships and environment, with scores ranging from 0 to 100. A higher score denotes a higher quality of life.

    Measured: Baseline and 6 months

  2. Change in quality of life (WHOQOL-BREF) between 0 and 6 months.

    Differences in WHOQOL-BREF between 0 and 6 months. The WHOQOL-BREF (World Health Organization Quality Of Life tool) consists of four dimensions: physical health, psychological health, social relationships and environment, with scores ranging from 0 to 100. A higher score denotes a higher quality of life.

    Measured: From baseline to 6 months

  3. Mental health at baseline

    Mental health assessed with MHC-SF tool

    Measured: Baseline

  4. Sexual health at baseline

    Sexual health defined by history of STIs and unprotected sexual intercourse

    Measured: Baseline

  5. Addictions at baseline

    Addictions assessed with ASSIST tool

    Measured: Baseline

  6. Screenings at baseline

    Participation in organized screenings for breast cancer, cervical cancer and colorectal cancer and individual screenings of STI

    Measured: Baseline

  7. Iatrogeny at baseline

    Complications related to hormone therapy or transition surgery

    Measured: Baseline

  8. Comorbidities at baseline

    Presence of comorbidities (cardiovascular diseases, cardiovascular risk factors, various pathologies, etc.)

    Measured: Baseline

  9. Violence experienced at baseline

    Types of violence experienced (verbal, physical, sexual, psychological, economic)

    Measured: Baseline

  10. Transition modalities

    Transition modalities (social transition, hormone therapy, surgery)

    Measured: At baseline, 6 months and 12 months

  11. Healthcare pathway

    Healthcare professionals consulted

    Measured: At baseline, 6 months and 12 months

  12. Self-medication

    Use of self-medication in the context of hormone therapy

    Measured: At baseline, 6 months and 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Mar 2025
  2. Study start28 Feb 2025 (estimated)
  3. Primary completion28 Feb 2027 (estimated)
  4. Study completion28 Feb 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06854965
Sponsor's protocol ID
CNGE-2022-07
Other IDs
N°ID RCB : 2024-A00504-43
Acronym
TRANSPOSE
Status last verified
Feb 2025
First submitted
3 Feb 2025
Last updated
3 Mar 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Transgender Persons, run by CNGE Conseil at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 3 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact El Mountacer Billah EL ABBASSI, Ph.D (+33 (0)763054551, e.elabbassi@cnge.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in quality of life (WHOQOL-BREF) between 0 and 12 months. (time frame: From enrollment to the last questionnaire at 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in